Clinical Trial Update: Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity, safety, tolerability, and memory priming potential of a Meningococcal C conjugate vaccine in healthy children; study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal C Conjugate Vaccine (Meningococcal C conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Prevention of Meningococcal Infection | Phase 3 | Status: COMPLETED